87Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Norway
Neuroscience Intelligence
Norway neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #27 of 50 · Data maturity A · Research score 35.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
20Recruiting trials
126Publications
46Institutions
Executive interpretation
Norway ranks #27 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Norwegian University of Science and Technology81 recruiting
Merck Sharp & Dohme LLC75 recruiting
Haukeland University Hospital64 recruiting
University of Oslo51 recruiting
Boehringer Ingelheim50 recruiting
Oslo University Hospital41 recruiting
NORCE Norwegian Research Centre AS31 recruiting
Nordlandssykehuset HF30 recruiting
Sorlandet Hospital HF30 recruiting
Diakonhjemmet Hospital20 recruiting
Disease activity
Parkinsons13trials
Depression10trials
Alzheimers9trials
Adhd7trials
Autism6trials
Epilepsy5trials
Sleep Disorders4trials
Stroke4trials
Neuro Oncology3trials
Migraine Headache3trials
Research institutions
OsloMet – Oslo Metropolitan UniversityOpenAlexlinked institution
Boehringer Ingelheim (Norway)OpenAlexlinked institution
Nordland Hospital TrustOpenAlexlinked institution
Sunnaas sykehusOpenAlexlinked institution
University Hospital of North NorwayOpenAlexlinked institution
Norwegian University of Life SciencesOpenAlexlinked institution
Telemark HospitalOpenAlexlinked institution
Vestre Viken Hospital TrustOpenAlexlinked institution
Lovisenberg Diakonale SykehusOpenAlexlinked institution
Hedmark University CollegeOpenAlexlinked institution
Clinical evidence trail
NCT07021274DBT Skill Training for Autistic Adults With Difficulties in Emotion Regulation.RECRUITING
NCT06998654Feasibility of a Digital Intervention for Patients Frequently Admitted to Psychiatric Acute WardsNOT_YET_RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineACTIVE_NOT_RECRUITING
NCT06299189A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine CareRECRUITING
NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisACTIVE_NOT_RECRUITING
NCT05839418Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)RECRUITING
Research evidence trail
PUBMEDClinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms.2027-01-01
PUBMEDInterstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.2026-12-01
PUBMEDInfection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.2026-12-01
PUBMEDDiagnostic-mortality discordance in ischaemic heart disease among patients with schizophrenia: A systematic review and meta-analysis.2026-12-01
PUBMEDComparing kappa free light chain index and CSF-restricted oligoclonal bands for detecting intrathecal immunoglobulin synthesis in a Norwegian cohort.2026-11-01
PUBMEDGenomic relationship between polyendocrine metabolic ovarian syndrome and bipolar disorder.2026-11-01
PUBMEDThe burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023.2026-11-01
PUBMEDObjectively Measured Cardiorespiratory Fitness as a Potential Biomarker for Alzheimer Disease Risk in Older Adults: Evidence from the Generation 100 Study.2026-11-01
PUBMEDStructural validity and internal consistency of the Client Satisfaction Questionnaire-8 among parents of children with ADHD: a cross-sectional study.2026-10-21
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.